Health Care & Life Sciences » Biotechnology | Nutra Pharma Corp.

Nutra Pharma Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
122.20
594.50
291.30
168.40
121.00
Cost of Goods Sold (COGS) incl. D&A
41.20
114.30
65.80
39.00
26.90
Gross Income
81.00
480.20
225.50
129.40
94.10
SG&A Expense
2,442.50
2,682.50
5,991.60
1,988.90
1,476.00
EBIT
2,361.40
2,202.30
5,766.10
2,043.50
1,381.90
Unusual Expense
1,843.30
202.60
781.10
1,129.70
2,288.20
Non Operating Income/Expense
19.20
-
27.60
19.40
-
Interest Expense
157.40
128.10
434.50
293.80
358.70
Pretax Income
4,343.00
2,533.00
5,392.00
3,447.60
4,028.70
Consolidated Net Income
4,343.00
2,533.00
5,392.00
3,447.60
4,028.70
Net Income
4,343.00
2,533.00
5,392.00
3,447.60
4,028.70
Net Income After Extraordinaries
4,343.00
2,533.00
5,392.00
3,447.60
4,028.70
Net Income Available to Common
4,343.00
2,533.00
5,392.00
3,447.60
4,028.70
EPS (Basic)
0.40
0.08
0.10
0.02
0.00
Basic Shares Outstanding
18,587.30
30,642.80
55,598.40
168,455.20
1,048,283.40
EPS (Diluted)
0.23
0.08
0.10
0.02
0.00
Diluted Shares Outstanding
18,587.30
30,642.80
55,598.40
168,455.20
1,048,283.40
EBITDA
2,346.50
2,185.70
5,754.90
2,034.80
1,375.70
Other Operating Expense
-
-
-
184.00
-

About Nutra Pharma

View Profile
Address
12538 West Atlantic Boulevard
Coral Springs Florida 33071
United States
Employees -
Website http://www.nutrapharma.com
Updated 07/08/2019
Nutra Pharma Corp. is a biopharmaceutical company, which is engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies & homeopathic and ethical drugs for the management of pain, neurological disorders, autoimmune and infectious diseases. Its products are Cobroxin, which is used for an over-the-counter pain reliever designed to treat moderate to severe chronic pain and Nyloxin Extra Strength, which is used for stronger versions of Cobroxin. The company was founded on February 1, 2000 and is headquartered in Coral Springs, FL.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.